The company's novel technology platform targets the protective barrier around bacteria through immune-enabling biologic therapies, which helps healthcare professionals to combat challenging infections fueled by biofilms and reduce antibiotic resistance. Clarametyx Biosciences is focused on developing targeted therapies to counteract biofilm-associated infections, which are notoriously difficult to treat with antibiotics. By addressing this critical unmet medical need, the company aims to improve patient outcomes and reduce healthcare costs associated with antibiotic resistance.